EGFR and lung cancer: An integrated approach of employing liquid biopsy and PGx for serial molecular profiling of EGFR mutant and resistant lung cancer patients at an individual level as well as at population subsets could represent a potential precise screening and monitoring tool in this era of precision oncology by identifying precise doses of TKIs against targetable EGFR mutations.